A bridging loan for the CellHeal and Innoventure deals and presumable capital injections therein. OPT's maverick CEO has shown himself to be very inexperienced in the world of finance and is now bargaining from a very weak position. Feel sorry for long term holders, but the science you all invested in very much still there. Just very poorly managed, both strategically (Board) and from a finance and business development perspective (exec's).
I've bought more down here knowing its a couple of binary options on its future. If it fails to get decent Innoventure or CellHeal deals, its future looking very doubtful.
OSX Price at posting:
4.6¢ Sentiment: Buy Disclosure: Held
